Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
NCT00036140 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2005-06-24
Summary
The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.
Conditions
Interventions
- DRUG
-
Investigational drug
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584 ·Status: RECRUITING
-
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
NCT04370483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
NCT00113204 ·Status: COMPLETED ·Phase: PHASE1
-
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT03389347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT00932698 ·Status: COMPLETED ·Phase: PHASE1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
NCT03091127 ·Status: COMPLETED
-
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
NCT02954796 ·Status: TERMINATED ·Phase: PHASE1
-
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
NCT01775553 ·Status: COMPLETED ·Phase: PHASE2
-
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
NCT05486975 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT07105059 ·Status: RECRUITING ·Phase: PHASE1
-
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178 ·Status: ACTIVE_NOT_RECRUITING
-
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
NCT01351623 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NCT05565807 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
NCT01410500 ·Status: APPROVED_FOR_MARKETING
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
NCT05286229 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
NCT01949532 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
NCT01792102 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
NCT00086216 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226 ·Status: COMPLETED
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
NCT05920876 ·Status: UNKNOWN ·Phase: PHASE1